Radiopharm Theranostics Ltd
ASX:RAD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Radiopharm Theranostics Ltd
Net Income (Common)
Radiopharm Theranostics Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
R
|
Radiopharm Theranostics Ltd
ASX:RAD
|
Net Income (Common)
-AU$36.7m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
Net Income (Common)
-$94.4m
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-1%
|
|
|
CSL Ltd
ASX:CSL
|
Net Income (Common)
$1.4B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
0%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Net Income (Common)
-AU$9.4m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Net Income (Common)
-AU$7.1m
|
CAGR 3-Years
53%
|
CAGR 5-Years
31%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Net Income (Common)
-AU$47.6m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
-29%
|
|
Radiopharm Theranostics Ltd
Glance View
Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-11-25. The firm is a developer of platform of radiopharmaceutical products for both diagnostic and therapeutic uses. The company has a pipeline of four licensed platform technologies, namely Nano- monoclonal antibodies (mAbs) technology, Pivalate, AVb6 Integrin and PSA-mAb. Nano-mAbs technology platform provides Nano-mAbs, which are made using genetically engineered camelid derived single domain antibodies (sdAb), that are labelled with radioisotopes to diagnose and treat specific cancers expressing HER-2, TROP-2, PD-L1 and PTK7 receptors. Pivalate is an F-FPIA radiotracer, and its technology is based on a short chain carbohydrate. Its clinical program includes five Phase I clinical trials, five Phase II clinical trials, and two Phase I clinical trials targeting a various cancer, including breast, lung, kidney, head and neck, pancreatic and brain. Its pipeline consists of RAD101, RAD102, RAD104, RAD105, RAD106, and RAD201 among others.
See Also
What is Radiopharm Theranostics Ltd's Net Income (Common)?
Net Income (Common)
-36.7m
AUD
Based on the financial report for Jun 30, 2025, Radiopharm Theranostics Ltd's Net Income (Common) amounts to -36.7m AUD.
What is Radiopharm Theranostics Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 3Y
-6%
Over the last year, the Net Income (Common) growth was 23%. The average annual Net Income (Common) growth rates for Radiopharm Theranostics Ltd have been -6% over the past three years .
